The UK is an attractive market for branded medicines as the pharmaceutical list price is negotiated independently of other countries, allowing for confidential discount agreements for reimbursement. In order to achieve this, products may have to undergo a NICE appraisal.
This guidance note outlines the top five reasons why products fail to achieve a positive NICE recommendation and details how to avoid common pitfalls. In addition, this guidance will present two case studies detailing previous experiences with NICE submissions, as well as detailing statistics for HTA submission outcomes since 2014.
This content is restricted to members. To view this content please register or login below to view this content.
